1. Home
  2. XOS vs MRKR Comparison

XOS vs MRKR Comparison

Compare XOS & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XOS
  • MRKR
  • Stock Information
  • Founded
  • XOS 2016
  • MRKR N/A
  • Country
  • XOS United States
  • MRKR United States
  • Employees
  • XOS N/A
  • MRKR N/A
  • Industry
  • XOS Construction/Ag Equipment/Trucks
  • MRKR Biotechnology: Pharmaceutical Preparations
  • Sector
  • XOS Consumer Discretionary
  • MRKR Health Care
  • Exchange
  • XOS Nasdaq
  • MRKR Nasdaq
  • Market Cap
  • XOS 37.9M
  • MRKR 35.8M
  • IPO Year
  • XOS N/A
  • MRKR N/A
  • Fundamental
  • Price
  • XOS $4.23
  • MRKR $3.03
  • Analyst Decision
  • XOS Buy
  • MRKR Strong Buy
  • Analyst Count
  • XOS 5
  • MRKR 1
  • Target Price
  • XOS $15.00
  • MRKR $19.00
  • AVG Volume (30 Days)
  • XOS 32.1K
  • MRKR 36.2K
  • Earning Date
  • XOS 11-13-2024
  • MRKR 11-22-2024
  • Dividend Yield
  • XOS N/A
  • MRKR N/A
  • EPS Growth
  • XOS N/A
  • MRKR N/A
  • EPS
  • XOS N/A
  • MRKR N/A
  • Revenue
  • XOS $62,863,000.00
  • MRKR $5,395,849.00
  • Revenue This Year
  • XOS $76.77
  • MRKR $35.94
  • Revenue Next Year
  • XOS $68.60
  • MRKR N/A
  • P/E Ratio
  • XOS N/A
  • MRKR N/A
  • Revenue Growth
  • XOS 81.07
  • MRKR 79.04
  • 52 Week Low
  • XOS $4.00
  • MRKR $2.44
  • 52 Week High
  • XOS $14.86
  • MRKR $6.16
  • Technical
  • Relative Strength Index (RSI)
  • XOS 40.70
  • MRKR 39.27
  • Support Level
  • XOS $4.11
  • MRKR $3.52
  • Resistance Level
  • XOS $5.45
  • MRKR $3.90
  • Average True Range (ATR)
  • XOS 0.33
  • MRKR 0.40
  • MACD
  • XOS 0.00
  • MRKR -0.12
  • Stochastic Oscillator
  • XOS 15.86
  • MRKR 0.00

About XOS Xos Inc.

Xos Inc is an electric mobility company. It designs and develops fully electric battery mobility systems specifically for commercial fleets. The company's primary focus is on medium- and heavy-duty commercial vehicles that travel on last mile routes. The company leverages its proprietary technologies to provide commercial fleets zero emission vehicles that are easier to maintain and more cost-efficient on a total cost of ownership basis than internal combustion engine and commercial EV counterparts.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Share on Social Networks: